# Follitropin Alpha

## Gonal-F 75IU inj

| 藥物代碼 | IGON |
| :--- | :--- |
| 適應症 | Anovulation including polycystic ovarian disease \(PCOD\) in women who have not responded to clomiphene citrate therapy. Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies \(ART\). |
| 副作用 | Local reactions at the inj site. Fever, arthralgia, pain in the lower abdominal region, nausea, vomiting, weight gain. |
| 禁忌 | Pregnancy & lactation, ovarian enlargement or cyst not due to polycystic ovarian disease, gynaecological haemorrhages of unknown aetiology, ovarian, uterine or mammary carcinoma, case of tumours of the hypothalamus & pituitary gland, hypersensitivity to follitropin α, FSH or to any of the excipients. When an effective response cannot be obtained, such as primary ovarian failure, malformation of sexual organs incompatible with pregnancy, fibroid tumours of the uterus incompatible with pregnancy. |
| 藥物保存方式 | N/A |
| 用法用量 | By SC inj. Women with anovulation \(including PCOD\) 75-150 iu daily & increased by 37.5 or 75 iu at 7 or 14 day intervals. Max daily dose: 225 iu. When an optimal response is obtained a single inj of up to 5,000 iu, up to 10,000 iu hCG should be given 24-48 hr after the last Gonal-F inj. The patient is recommended to have coitus on the day of, & the day after hCG administration. Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilization or other ART 150-225 iu of Gonal-F daily, commencing on day 2 or 3 of the cycle. Dose adjustment should not exceed 450 iu daily. A single inj of up to 10,000 iu hCG is administered 24-48 hr after the last Gonal-f inj to induce final follicular maturation. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | Micromedex: Infant risk cannot be ruled out. |
| 注射劑給藥建議途徑 | SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Gonal-f inj 450 IU

| 藥物代碼 | IGON4 |
| :--- | :--- |
| 適應症 | 女性患者 \(1\)婦女經CLOMIPHENE CITRATE治療，仍無法排卵者\(含多囊性卵巢症，PCOD\) 。\(2\)對於實施人工生殖協助技術\(ART\)，如體外受精\(IVF\)，配子輸卵管植入\(GIFT\)，合子輸卵管植入\(ZIFT\)的病人，可刺激其多濾泡發育。\(3\)與黃體刺激素\(LH\)併用，使用於嚴重缺乏黃體刺激激素與濾泡刺激激素患者的濾泡刺激成長。男性患者治療男性對於患有先天或後天性腺刺激素不足之性腺功能低下症，併用人類絨毛膜性腺刺激素\(hCG\)，刺激精子生成。 |
| 副作用 | Local reactions at the inj site. Fever, arthralgia, pain in the lower abdominal region, nausea, vomiting, weight gain. |
| 禁忌 | Pregnancy & lactation, ovarian enlargement or cyst not due to polycystic ovarian disease, gynaecological haemorrhages of unknown aetiology, ovarian, uterine or mammary carcinoma, case of tumours of the hypothalamus & pituitary gland, hypersensitivity to follitropin α, FSH or to any of the excipients. When an effective response cannot be obtained, such as primary ovarian failure, malformation of sexual organs incompatible with pregnancy, fibroid tumours of the uterus incompatible with pregnancy. |
| 藥物保存方式 | 室溫 |
| 用法用量 | By SC inj. Women with anovulation \(including PCOD\) 75-150 iu daily & increased by 37.5 or 75 iu at 7 or 14 day intervals. Max daily dose: 225 iu. When an optimal response is obtained a single inj of up to 5,000 iu, up to 10,000 iu hCG should be given 24-48 hr after the last Gonal-F inj. The patient is recommended to have coitus on the day of, & the day after hCG administration. Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilization or other ART 150-225 iu of Gonal-F daily, commencing on day 2 or 3 of the cycle. Dose adjustment should not exceed 450 iu daily. A single inj of up to 10,000 iu hCG is administered 24-48 hr after the last Gonal-f inj to induce final follicular maturation. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | Micromedex:Infant risk cannot be ruled out |
| 注射劑給藥建議途徑 | SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

